Chugai Pharmaceutical Co., Ltd. (4519.T) is in Healthcare, Drug Manufacturers - General, based in Japan, listed on Tokyo. Market cap 9.91T JPY. 52-week range 5,974.00 to 10,700.00 JPY. Trailing P/E 21.0. Data as of 2026-10-09.
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 ...